Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL)
- 22 April 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 134 (1), 419-428
- https://doi.org/10.1007/s10549-012-2066-9
Abstract
Adjuvant hormonal therapy for non-metastatic hormone receptor (HR)-positive breast cancer decreases risk of breast cancer recurrence and increases survival. However, some women do not initiate this life-saving treatment. We used a prospective cohort design to investigate factors related to non-initiation of hormonal therapy among women with newly diagnosed, non-metastatic HR-positive breast cancer recruited from three U.S. sites. Serial interviews were conducted at baseline and during treatment to examine sociodemographic factors, tumor characteristics, and treatment decision-making factors. Multivariate modeling assessed associations between variables of interest and hormonal therapy initiation. Of 1,050 breast cancer patients recruited, 725 (69 %) had HR-positive breast cancer, of whom 87 (12.0 %) based on self-report and 122 (16.8 %) based on medical record/pharmacy fill rates did not initiate hormonal therapy. In a multivariable analysis, non-initiation of hormonal therapy, defined by medical record/pharmacy, was associated with having greater negative beliefs about efficacy of treatment (OR 1.42, 95 % CI 1.18–1.70). Non-initiation was less likely in those who found the quality of patient/physician communication to be higher (OR 0.96, 95 % CI 0.93–0.99), the hormonal therapy treatment decision an easy one to make (OR 0.45, 95 % CI 0.23–0.90) or neither easy nor difficult (OR 0.34, 95 % CI 0.20–0.58); and had more positive beliefs about hormonal therapy efficacy (OR 0.40, 95 % CI 0.34–0.62). Factors influencing non-initiation of adjuvant hormonal therapy are complex and influenced by patient beliefs regarding treatment efficacy and side effects. Educational interventions to women about the benefits of hormonal therapy may decrease negative beliefs and increase hormone therapy initiation.Keywords
This publication has 48 references indexed in Scilit:
- Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancerBreast Cancer Research and Treatment, 2011
- Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancerBreast Cancer Research and Treatment, 2010
- Explanations for side effect aversion in preventive medical treatment decisions.Health Psychology, 2009
- Adherence to tamoxifen over the five-year courseBreast Cancer Research and Treatment, 2006
- Adherence to MedicationThe New England Journal of Medicine, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerThe New England Journal of Medicine, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerThe New England Journal of Medicine, 2003
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987